Upstate Active Clinical Trials

Study Title:

A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma

What is the purpose of the study?

Study to look at experimental drug combinations by adding brentuximab vedotin or crizotinib to standard chemotherapy in the hopes of finding a more effective treatment for ALCL.

Upstate Institutional Review Board (IRB) Number:

542077

Study/Protocol ID:

ANHL12P1

Study Phase:

II

Patient Age Group:

Children

Principal Investigator:

Karol H Kerr, MD

ClinicalTrials.Gov ID:

NCT01979536

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Beatriz Kovar
Phone: 315-464-7232
Email: kovarb@upstate.edu

Return to Previous Page || Search Again